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ABSTRACT
Diseases of the human brain are almost universally
attributed to malfunction or loss of nerve cells. However,
a considerable amount of work has, during the last decade,
expanded our view on the role of astrocytes in CNS (central
nervous system), and this analysis suggests that astrocytes
contribute to both initiation and propagation of many (if
not all) neurological diseases. Astrocytes provide metabolic
and trophic support to neurons and oligodendrocytes.
Here, we shall endeavour a broad overviewing of the
progress in the field and forward the idea that loss of
homoeostatic astroglial function leads to an acute loss
of neurons in the setting of acute insults such as
ischaemia, whereas more subtle dysfunction of astrocytes
over periods of months to years contributes to epilepsy and
to progressive loss of neurons in neurodegenerative
diseases. The majority of therapeutic drugs currently in
clinical use target neuronal receptors, channels or
transporters. Future therapeutic efforts may benefit by a
stronger focus on the supportive homoeostatic functions
of astrocytes.
Key words: aging, astrocyte, brain, calcium, disease,
supportive cell, transmitter.
INTRODUCTION
Astrocytes are specialized glial cells that are ubiquitously
present in all regions of the CNS (central nervous system).
Although astrocytes were first identified over 120 years ago
and their responses to CNS injury have been recognized for
over a century (Kettenmann and Verkhratsky, 2008), for much
of this time they have been regarded largely as passive cells
providing structural support for neuronal networks; and the
notions that astrocytes might make important contributions
to CNS function, or that dysfunctions of astrocytes might
contribute to CNS pathological remodelling and disease, were
generally not considered. In spite of this long ‘passive’ history,
ideas about astrocytes are now changing radically. A steadily
growing body of data has over the last 25 years established a
variety of essential functions for astrocytes in the healthy
nervous system and in the response to injury and disease.
Moreover, mechanisms are being elucidated through which
the loss or gain of astrocyte functions can contribute to
dysfunction or degeneration as well as repair and post-
disease remodelling of the CNS. Based on this information,
the multiple roles of astroglia, which determine the pro-
gression and outcome of neurological diseases, are emerging,
and it is becoming clear that astrocytes are involved in
various aspects of disease initiation, progression and
1 Correspondence may be addressed to either of these authors (email Nedergaard@urmc.rochester.edu or Alexej.Verkhratsky@manchester.ac.uk).
Abbreviations: Ab, amyloid b-peptide; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; AMPA, a-amino-3-hydroxy-5-methylisoxazole-4-propionic acid; CNS,
central nervous system; EAAT1, excitatory amino acid transporter 1; EL, epileptic; EPO, erythropoietin; GABA, c-aminobutyric acid; GAT-3, GABA transporter 3; GFAP, glial
fibrillary acidic protein; mGluR, metabotropic glutamate receptor; OGD, oxygen glucose deprivation; TSP1/2, thrombospondins 1 and 2.
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resolution. Knowledge emerging about many different
aspects of neuropathologies clearly indicates that astrocytes
contribute to many neurological diseases and in some cases,
such as Alexander disease, is the direct cause of the
neurodegeneration. As the astrocyte contribution to specific
clinico-pathological entities is being defined, it is useful to
compare the astroglial involvement across a number of
diseases. We will here specifically review the role of astrocytes
in epilepsy, stroke and neurodegenerative diseases. Alexander
disease presents clinically as a classical early childhood
leucodystrophy with seizure, myelin loss and neuronal
degeneration, but is caused by mutation and accumulation
of GFAP (glial fibrillary acidic protein). The fundamental fact
that a defect in astrocytes underlies dysfunction and death of
neurons and oligodendrocytes is discussed.
ASTROCYTES CONTROL CNS HOMOEOSTASIS
Astrocytes are the most numerous, morphologically hetero-
geneous and functionally diverse neuroglial cells. Indeed,
even the definition of astrocyte does not really exist, as the
‘astroglia’ as a cell class covers all non-myelinating macroglial
cells in the CNS, which along with classical protoplasmic and
fibrous astrocytes includes, for example, such different
cellular entities as retinal Muller radial glial cells, tanycytes
in hypothalamus, pituicytes in the neuro-hypophysis, and
ependymocytes, choroid plexus cells and retinal pigment
epithelial cells that line the ventricles or the subretinal space
(Reichenbach and Wolburg, 2005; Verkhratsky and Butt,
2007). All these cells have, however, one thing in common:
their main function is in providing for CNS homoeostasis and
therefore astrocytes can be broadly defined as ‘homoeostatic
neuroglial cells’.
Astrocytes participate in controlling CNS homoeostasis
at many levels. Astroglia is critical for maintaining
molecular homoeostasis (astrocytes regulate concentra-
tions of ions, neurotransmitters and neurohormones in the
CNS (Newman, 1995; Danbolt, 2001); metabolic homoeo-
stasis (astroglia accumulate energy substrates and supplies
neurones with lactate; Magistretti, 2006), cellular hom-
oeostasis (astrocytes are directly involved in neurogenesis;
Alvarez-Buylla et al., 2001), morphological homoeostasis
(astroglia define neural cell migration during development,
control synaptogenesis/synaptic pruning and shape the
micro-architecture of grey matter (Nedergaard et al., 2003;
Pfrieger, 2009), and organ homoeostasis (astroglia control
the formation and maintenance of the blood–brain barrier;
Abbott, 2005). Furthermore, astrocytes appear to be
critically important for brain chemosensing, being able to
detect systemic fluctuations in CO2, pH and Na
+ and
initiate behavioural homoeostatic programmes (Shimizu
et al., 2007; Gourine et al., 2010; Huckstepp et al., 2010;
Gourine and Kasparov, 2011).
Astrocytes also act as integrators in the CNS. In the grey
matter, astrocytes create relatively independent neuro-
vascular units connected to the capillaries via astroglial
perivascular processes. Recent findings show that astrocytes
produce and release various molecular mediators, such as
prostaglandin E, nitric oxide and arachidonic acid, which can
increase or decrease CNS blood vessel diameter and blood
flow in a co-ordinated manner (Gordon et al., 2007; Iadecola
and Nedergaard, 2007). Furthermore, astrocytes appear to be
primary mediators of changes in local CNS blood flow in
response to changes in neuronal activity (Schummers et al.,
2008; Wolf and Kirchhoff, 2008; Koehler et al., 2009).
Astrocytes are fundamental for synaptic transmission and
synaptic plasticity. Astrocyte processes that envelop or are in
close proximity to synapses provide for spatial specificity of
synaptic inputs through isolating individual synapses with
astroglial ‘cradle’ and maintain the fluid, ion, pH and
transmitter homoeostasis and provide local metabolic support
that are critical for synaptic transmission (Bourne and Harris,
2008; Nedergaard and Verkhratsky, 2012). Astrocytes are
endowed with multiple neurotransmitter receptors that allow
them to monitor neuronal activity (Verkhratsky, 2010; Lalo
et al., 2011a, 2011b) and, moreover, astrocytes secret multiple
neurotransmitters and neurohormones (e.g. ATP/purines,
glutamate, D-serine, etc.: Halassa et al., 2007a, 2007b;
Shigetomi et al., 2008; Perea et al., 2009) that can regulate
functional activity of many tens of thousands of synapses
located within astroglial territorial domain by a paracrine
route. As already mentioned above, astrocyte-derived mole-
cules appear to play critical roles in the formation,
maintenance and pruning of synapses (Christopherson
et al., 2005; Stevens et al., 2007; Barres, 2008). In addition,
polypeptide cytokines such as tumour necrosis factor-a
produced by astrocytes as well as microglia can influence
homoeostatic synaptic scaling by inducing the insertion of
AMPA (a-amino-3-hydroxy-5-methylisoxazole-4-propionic
acid) receptors at post-synaptic membranes (Stellwagen and
Malenka, 2006). Astrocytes are also critical for maintaining
glutamatergic transmission by recycling glutamate through
the glutamate–glutamine shuttle for subsequent reconver-
sion into active transmitter in the synaptic terminal (Danbolt,
2001; Sattler and Rothstein, 2006).
GENERAL PATHOPHYSIOLOGY OF ASTROGLIA:
NEUROPATHOLOGY AS HOMOEOSTATIC
FAILURE
Every disease of the CNS can be regarded as a homoeostatic
failure either inherited (loss of homoeostatic function) or
acute (trauma or stroke) or chronic (neurodegeneration). The
initiation and progression of these diseases are determined by
the degree of homoeostatic loss, which can be either general or
function-specific. The general failure is characteristic for acute
A. Verkhratsky and others
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insults (trauma, stroke or toxic attack), which compromise
brain homoeostasis on many levels from organ (disruption of
blood–brain barrier) to metabolic (shutting down the brain
energetics) and molecular (loss of neurotransmitter homoeo-
stasis with subsequent excitotoxicity). The specific homoeo-
static failures are operative in many forms of chronic
pathology, when for example down-regulation of glutamate
transporters induces neuronal death in Wernicke encephalo-
pathy. In many pathologies, the homoeostatic failure pro-
gresses and broadens when for example initial disruptions of
protein catabolism trigger inflammatory reactions, initiate
cytotoxicity and compromise the blood–brain barrier (as
happens in various neurodegenerative processes).
The systemic homoeostatic function of astroglia makes
these cells the main targets for neuropathology (Giaume et al.,
2007; Verkhratsky and Parpura, 2010). Astrocytes form the
brain defence system by virtue of many homoeostatic
molecules expressed in astroglia; using these molecules,
astrocytes contain the damage and sustain neuronal survival
through maintaining CNS homoeostasis. One of many
examples is represented by maintaining brain metabolism
following ischaemia/hypoglycaemia, when astrocyte glycogen
breaks down to lactate that is transferred to adjacent neural
elements where it is used aerobically as fuel (Brown and
Ransom, 2007; Brown et al., 2007; Suh et al., 2007). When
and if astroglial homoeostatic mechanisms are exhausted the
nervous tissue dies.
At the same time all glial homoeostatic mechanisms are
endowed with an inherent dichotomy – being developed as
survivalistic and protective they may turn to be deleterious
and toxic. In conditions of severe insult astrocytes can assume
damaging and toxic proportions (Figure 1). For example
aquaporins expressed in astroglia are critical for water
movements through brain tissue, but they can also be
instrumental in mediating oedema in pathology (Zador et al.,
2009). Similarly, K+ channels responsible for potassium
buffering when under pathological stress can add to
accumulation of extracellular K+ and mediate spreading
depression (Nedergaard and Dirnagl, 2005). The connexins,
which connect astrocytes into multicellular syncytia can
become the passages for death signals underlying the spread
of necrosis through ischaemic penumbra (Lin et al., 1998),
whereas depolarization and Na+ accumulation in astroglia
triggers reversal of glutamate transporters which increase
glutamate excitotoxicity.
ASTROCYTE RESPONSES TO INJURY AND
DISEASE: REACTIVE ASTROGLIOSIS AND SCAR
FORMATION
Astrocytes respond to all forms of CNS injury and disease
through a process known as reactive astrogliosis. Substantial
progress has been made recently in determining functions
and mechanisms of reactive astrogliosis and in identifying
roles of reactive astrocytes in CNS disorders and pathol-
ogies (Figure 2). For the sake of clarity, it is useful to begin
with a working definition of the terms ‘reactive astrogliosis’
and ‘glial scar formation’ (Sofroniew, 2009; Sofroniew
and Vinters, 2010). These terms are not synonymous.
Contrary to commonly held beliefs, reactive astrogliosis is
not a simple all-or-none stereotypic phenomenon. Instead,
reactive astrogliosis is a finely gradated continuum of
changes that occur in context-dependent manners regu-
lated by specific molecular signalling events. These
changes range from reversible alterations in gene express-
ion and cell hypertrophy with preservation of cellular
domains and tissue structure, to long lasting scar formation
with rearrangement of tissue structure (Sofroniew, 2009;
Sofroniew and Vinters, 2010). Based on a large body of
observations in experimental animals and human patho-
logical specimens, a definition of reactive astrogliosis has
recently been proposed includes several grades of severity
of reactive astrogliosis and glial scar formation that may be
encountered in experimental and clinical histopathological
examinations (Sofroniew, 2009; Sofroniew and Vinters,
2010). Although the increasing severities of reactive
astrogliosis transition seamlessly along a continuum, it is
convenient for purposes of description and classification to
recognize several broad categories.
Mild to moderate reactive astrogliosis consists of changes
(up- or down-regulation) in gene expression and hypertrophy
of cell body and processes without substantive loss of individual
astrocyte domains and little or no astrocyte proliferation; up-
regulation of GFAP expression is prominent. This type of
response is generally associated with mild non-penetrating and
non-contusive trauma, diffuse innate immune activation (viral
infections, system bacterial infections) and areas that are some
distance to focal CNS lesions. Because there is little or no
reorganization of tissue architecture, if the triggering mech-
anism is able to resolve, then mild or moderate reactive
astrogliosis exhibits the potential for resolution in which
the astrocytes return to an appearance similar to that in healthy
tissue (Sofroniew, 2009; Sofroniew and Vinters, 2010).
Severe diffuse reactive astrogliosis also consists of changes
(up- or down-regulation) in gene expression with pro-
nounced up-regulation of GFAP expression and hypertrophy
of cell body and processes, but in addition includes astrocyte
proliferation and loss of individual astrocyte domains with
substantive intermingling and overlapping of neighbouring
astrocyte processes. These changes can result in long-lasting
reorganization of tissue architecture that can extend
diffusely over substantive areas. This type of response is
generally found in areas surrounding severe focal lesions,
infections or areas responding to chronic neurodegenerative
triggers, and because there can be considerable tissue
reorganization, the potential for resolution and return to
normal structure is reduced (Sofroniew and Vinters, 2010).
Severe reactive astrogliosis with compact glial scar
formation also includes changes in gene expression, cellular
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hypertrophy and astrocyte proliferation, with pronounced
overlapping of processes to form compact borders around
areas of severe tissue damage, necrosis, infection or
autoimmune-triggered inflammatory infiltration (Bush
et al., 1999; Faulkner et al., 2004; Drogemuller et al.,
2008; Herrmann et al., 2008; Voskuhl et al., 2009). These glial
scars include other cell types, in particular fibromeningeal
and other glial cells (Bundesen et al., 2003; Herrmann et al.,
2008; Sofroniew, 2009; Sofroniew and Vinters, 2010), and
deposit collagenous extracellular matrix that contains many
molecular cues that inhibit axonal and cellular migration
(Silver and Miller, 2004). Triggering insults include penetrat-
ing trauma, severe contusive trauma, invasive infections or
abscess formation, neoplasm, chronic neurodegeneration,
or systemically triggered inflammatory challenges. It is
noteworthy that the glial scar formation is associated with
substantive tissue reorganization and structural changes
that are long lasting and persist long after the triggering
insult may have resolved.
The functional roles exerted by reactive astrocytes at
different points along their continuum of potential responses
to different kinds and severities of CNS insults are only
beginning to be understood. Although astrogliosis and scar
formation have often been viewed as maladaptive and purely
detrimental responses, this is not the case. There are now
many different kinds of evidence in vivo and in vitro that
reactive astrocytes maintain their homoeostatic mechanisms
and can protect CNS cells and tissue in various ways,
including by (i) uptake of potentially excitotoxic glutamate
(Rothstein et al., 1996; Bush et al., 1999; Swanson et al.,
Figure 1 General pathophysiology of astroglia
The homoeostatic cascades expressed in astrocytes control various aspects of CNS homoeostasis including extracellular ion
homoeostasis (K+ buffering via Kir channels, Na/K pump and K transporters), regulate movements and distribution of water (via
aquaporins and connexins), control extracellular concentration of neurotransmitters (by dedicated transporters) and provide the main
reactive oxygen species scavenging system. In pathological conditions, the very same systems may contribute to brain damage.
Failure in water transport triggers brain oedema, reversal of neurotransmitter transporters contributes to glutamate excitotoxicity,
inadequate K+ buffering promotes further overexcitation of neural cells and spreading depression, and connexins become a conduit
for death signals.
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2004); (ii) protection from oxidative stress via glutathione
production (Chen et al., 2001; Shih et al., 2003; Swanson et al.,
2004; Vargas et al., 2008); (iii) protection via adenosine release
that exerts systemic inhibitory and anti-inflammatory action
(Lin et al., 2008); (iv) protection from NH4
+ toxicity (Rao et al.,
2005); (v) protection by degradation of Ab (amyloid b-peptide;
Koistinaho et al., 2004); (vi) facilitating blood–brain barrier
repair (Bush et al., 1999); (vii) reducing vasogenic oedema after
trauma, stroke or obstructive hydrocephalus (Bush et al., 1999;
Zador et al. 2009); and (viii) stabilizing extracellular fluid and
ion balance and reducing seizure threshold (Zador et al., 2009).
Different types of transgenic models from different laborat-
ories show that either ablation or attenuation of reactive
astrogliosis causes increased lesion size, increased neuronal
loss, demyelination and exacerbated loss of function after
traumatic injury, stroke, autoimmune attack or infection (Bush
et al., 1999; Faulkner et al. 2004; Myer et al., 2006; Okada et al.,
2006; Drogemuller et al., 2008; Herrmann et al., 2008; Li
et al., 2008; Voskuhl et al., 2009). Together, these findings
indicate that reactive astrocytes exert essential neuroprotec-
tive functions. In addition, experimental evidence indicates
that reactive astrocytes play important roles in regulating CNS
inflammation, and that astrocyte scars act as essential
functional barriers that restrict the migration of inflammatory
cells and infectious agents and limit spread into adjacent




In considering how astrocyte dysfunction contributes to
neurological disease, interpreting most models and natural
diseases is complicated since there is presumed to be pre-
existing injury to other cell types that then induces the
changes in astrocytes. It is worth considering the simpler
situation where astrocytes are clearly the primary instig-
ator of disease – Alexander disease. This rare disorder arises
from mutations in the major intermediate filament protein
of astrocytes, GFAP (Brenner et al., 2001). Although GFAP
is expressed at lower levels in a number of cell types
throughout the body, many lines of evidence point to
initial dysfunction of astrocytes as the key initiating event
that then leads to a cascade of effects, ultimately
affecting every other cell type in the CNS (Brenner et al.,
2009).
Alexander disease is generally classified among the
leucodystrophies because the initial descriptions primarily
focused on younger onset patients who had dramatic
white matter deficits, especially involving the frontal
lobes. From its initial description (Alexander, 1949), the
disease was associated with distinctive pathology involving
accumulations of cytoplasmic protein aggregates within
the cell bodies and processes of astrocytes, known as
Rosenthal fibres, which contain GFAP and other proteins
(Figure 3). The most common classification is based on age
of onset (early, juvenile and adult; Li et al., 2005). The
younger patients typically have seizures or any of several
psychomotor delays as their initial symptoms, with
forebrain predominance to their lesions. In contrast, the
older patients typically present with gait disturbances,
bulbar signs, or autonomic dysfunction, and have a
hindbrain predominance of their lesions, sometimes
including atrophy of the medulla and cervical spinal cord.
All forms are typically progressive, with median survivals
reported as 3.6 years for the early onset group and 8 years
for the juvenile group (and undefined for adult) (Li et al.,
2005). A more recent classification recommends division
into just two groups, Types 1 and 2, based on particular
Figure 2 Appearance of astrocytes and different types of reactive astrocytes in mouse cerebral cortex
Images show immunohistochemistry for the intermediate filament protein, GFAP, which visualizes the cell cytoskeleton. (A) In healthy
cortex, some, but not all astrocytes express detectable levels of GFAP; cell bodies are small and the cytoskeleton is thin and restricted
largely to the proximal portions of cell processes. (B) In response to the bacterial antigen, lipopolysaccharide (LPS) injected into the
lateral cerebral ventricle, cortical astrocytes become moderately reactive, with up-regulation of GFAP expression such that it is now
detectable in all astrocytes. In addition, there is substantial hypertrophy of the astrocyte cell bodies as well as hypertrophy of stem
processes and associated cytoskeleton. However, there is no astrocyte proliferation and individual cells continue to respect their
individual, non-overlapping domains. (C) In response to a severe traumatic injury that creates a lesion (L) with tissue necrosis and
invasion of inflammatory cells, astrocytes not only become reactive but also proliferate in the immediate vicinity of the lesion and form
a scar with a dense scar border (SB) that comprises many newly generated astrocytes that do not exhibit individual domains and instead
have many overlapping and intermingling processes. All images are at the same magnification. Scale bar520 mm (Photos courtesy of the
Sofroniew laboratory).
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clustering of symptoms (Prust et al., 2011). In addition,
survival may be longer for both groups than previously
imagined.
As noted above, all forms of Alexander disease are now
associated with mutations in GFAP (Li et al., 2005). Most of
these mutations are heterozygous single base pair changes
within the coding region that predict single amino acid
changes in the translated protein. A small number of
mutations involve in frame deletions or insertions. All are
heterozygous, genetically dominant, with nearly 100%
penetrance. A very small number of patients with presumed
Alexander disease have no identifiable coding region
mutations, but in theory a similar disease could arise from
other types of alterations at the GFAP locus such as promoter
mutations or gene duplication. Most mutations occur de novo
(as expected when survival is short), although later onset
patients can survive to reproductive age and transmit the
mutations to subsequent generations with typical autosomal
dominant patterns of inheritance. A recent population-based
survey in Japan reported a prevalence of 1 in 2.7 million, but
this value may be low because the study excluded severely
affected infants who died at very young ages and adult-onset
patients are often missed (Yoshida et al., 2011).
How do GFAP mutations cause disease? There are no clear
answers to this question yet, partly a reflection of how little
we understand the normal functions of GFAP and other
intermediate filaments. It is interesting that the known
disease-causing mutations (now numbering 71 out of a
total 432 amino acid sequence) are sprinkled through-
out the rod and tail domains (Brenner et al., 2009; http://
www.waisman.wisc.edu/alexander/mutations). The surprising
fact is that all of these mutations essentially cause the same
disease. Genotype–phenotype correlations are still only
speculative, due in large part to the paucity of patients
with any particular mutation. While the R239H mutations
seem to consistently cause early onset disease, the R416W
mutation has been found in all forms of the disease. Several
examples exist of the same mutation causing different forms
of the disease, even within the same family (Stumpf et al.,
2003; Messing et al., 2011). It is possible that head domain
mutations do occur, but are early lethal and so never reach
the stage of diagnosis.
Unlike most of the other intermediate filament diseases,
GFAP mutations appear to act in a gain-of-function fashion. In
support of this hypothesis is the absence of truncation or null
mutations among the human patients (Brenner et al., 2009), the
dissimilarity in phenotype between mouse knockouts of GFAP
and the human disease (Gomi et al., 1995; Pekny et al., 1995;
McCall et al., 1996), and the finding that overexpression of
wild-type protein alone to sufficient levels is lethal and
replicates the key pathological feature of the disease, Rosenthal
fibres (Messing et al., 1998). Using cell culture models, Tang and
Goldman (2006) have found that forced overexpression of wild-
type and mutant GFAP leads to pleiotropic effects, with
activation of JNK (c-Jun N-terminal kinase) and p38 MLK
(mixed-lineage kinase) stress pathways and impairment of the
proteasome. One or more positive feedback loops then form to
further enhance the toxic accumulation of GFAP. Paradoxically,
there is also enhancement of autophagy, which occurs by both
mTOR (mammalian target of rapamycin)-dependent and
-independent mechanisms (Tang and Goldman, 2008). Mouse
models show evidence of oxidative stress, particularly in white
matter (Hagemann et al., 2006), and the cell culture models
display increased sensitivity to camptothecin-induced apo-
ptosis and H2O2-induced cell death (Tang and Goldman, 2006;
Cho and Messing, 2009).
How GFAP mutations and/or excess activate these stress
pathways and impact on the protein degradation machinery
of the cell is not clear. Normally GFAP exists in an
equilibrium between Triton-X soluble and insoluble pools,
with the majority being insoluble. These two pools roughly
correspond to the process by which monomers (which are
soluble) gradually assemble into higher-ordered structures
and finally mature intermediate filaments (which are
insoluble). Expression of mutant GFAPs cause a distinct shift
in this equilibrium towards the insoluble pool, perhaps
reflecting the unknown proportion that accumulates in the
Rosenthal fibres themselves (Hsiao et al., 2005).
Interestingly, the shift towards insolubility is also displayed
by the small stress protein aB-crystallin, which is a normal-
binding partner of GFAP and accumulates in the Rosenthal
fibres as well (Der Perng et al., 2006; Perng et al., 2008).
Studies in mouse models have shown that aB-crystallin
deficiency increases mortality (Hagemann et al., 2009).
Perhaps aB-crystallin is sequestered to the point of
deficiency? Hence, one hypothesis is that the Alexander
phenotype reflects a combination of both gain of function
(GFAP) and loss of function (aB-crystallin). One cannot
blame the full Alexander phenotype on aB-crystallin
deficiency alone; however, since mouse knockouts of aB-
crystallin and humans with a nearly complete deletion at
Figure 3 Immunostaining for GFAP in brain tissue from mouse models of
Alexander disease showing abundant Rosenthal fibres in the periven-
tricular region
GFAP immunohistochemistry in the periventricular white matter of (A) wild-
type or (B, C) knock-in point mutants expressing either R76H or R236H
mutant forms of GFAP (equivalent to the common R79H and R239H
mutations in human GFAP). Abundant Rosenthal fibres with increased
immunoreactivity for GFAP are particularly evident in periventricular and
white matter astrocytes of adult mice (3 months old). Reproduced with
permission from Figures 3(A)–3(C) of Hagemann et al. (2006) E2006 Society
for Neuroscience.
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this locus have predominantly skeletal muscle phenotypes,
with no evidence yet for neurological consequences (Brady
et al., 2001; Del Bigio et al., 2011).
Are the astrocytes in Alexander disease simply extreme
examples of reactive astrocytes? They do share some properties
considered fundamental to the gliotic phenotype, such as
increased expression of GFAP and the endothelin B receptor
(Hagemann et al., 2006). Recent studies point towards impaired
expression of the glutamate transporter Glt-1 (Hagemann et al.,
2009; Tian et al., 2010), perhaps analogous to what occurs in
other neurodegenerative diseases such as ALS (amyotrophic
lateral sclerosis). However, as (probably) noted above, reactive
astrocytes are highly diverse and likely differ considerably
depending on the nature of insult, location in the nervous
system, and stage of disease (Hamby and Sofroniew, 2010). In
the case of Alexander disease, the initial insult is mutant GFAP,
which may produce toxic forms that are unique to this condition
and cause types of astrocyte dysfunction different from those in
other types of reactive astrocytes. Interestingly, the Goldman
laboratory has identified toxic oligomers in the soluble pool of
GFAP that may be responsible for the impairment in proteasome
function noted above, and also showed that this effect could be
mitigated by co-expression of the small stress protein, aB-
crystallin (Tang et al., 2010). That aB-crystallin may be a key
modifier of astrocyte function, and potential therapeutic target,
is also indicated by its ability to rescue mouse models of
Alexander disease from an otherwise lethal phenotype induced
by GFAP mutations and excess (Hagemann et al., 2009).
Despite the many gaps in our understanding of the
mechanisms and impact of astrocyte dysfunction in
Alexander disease, several strategies for therapy have been
suggested (Messing et al., 2010). The most obvious approach
is to reduce the expression or accumulation of GFAP, so as to
avoid the initial insult that drives the entire process. One drug
screen has already been completed using wild-type astrocytes
in primary culture (Cho et al., 2010), and similar drug screens
using astrocytes expressing mutant protein are underway. A
second approach is to target downstream effects of GFAP
toxicity, such as the proposed change in Glt-1 expression.
Ceftriaxone, already in clinical trials for ALS, may be a good
candidate for such an approach (Rothstein et al., 2005). Final-
ly, manipulation of stress pathways such as those regulating
aB-crystallin may prove effective. New Drosophila models of
GFAP toxicity in glia have just been developed that will prove
especially valuable for dissecting the pathways to dysfunc-




Stroke remains a major source of death and disability in the
United States as a stroke-induced death occurs every 3 min.
Over the past couple of decades, dozens of clinical trials
tested neuroprotective agents in the treatment of stroke.
These efforts largely targeted neuronal-specific cell death
ignoring the roles of other cell types such as astrocytes,
microglia and the vasculature. The failure of these trials has
evoked a keen interest in elucidating the influence of non-
neuronal cell types on brain survival and function during
stroke. As discussed in detail at the beginning of this paper a
large body of literature supports a pivotal influence of
astrocytes on multiple processes within the brain, which
impact the survival and function of neurons as well as the
vasculature. Yet, astrocyte function may be both protective
and harmful. Interestingly, the same molecule released by
astrocytes may have opposing actions on brain tissue viability
depending on their temporal expression following stroke.
Determining the critical temporal windows and the molecular
mechanisms by which astrocyte function either reduces or
enhances injury is important to discern and will be a matter
of the discussion to follow.
During the first few hours after the onset of ischaemia, the
acute phase of stroke, several astrocyte functions may reduce
ischaemic damage including the uptake of glutamate,
scavenging of reactive oxygen species and uptake of K+
(Chen and Swanson, 2003). Yet many of these functions are
likely compromised in the inhospitable environment of the
ischaemic brain. In the stroke core, where glucose and oxygen
supply are greatly reduced, the severe loss of energy
substrates can lead to astrocyte membrane depolarization
and death. If the membrane potential of astrocytes is
compromised too severely, glutamate flux may reverse
leading to release of glutamate by astrocytes and neuronal
excitotoxicity. Although astrocytes in culture are more
tolerant to OGD (oxygen glucose deprivation) compared with
neurons, they are particularly susceptible to damage during
acidosis and when ion concentrations of Na+ and Ca2+ are
altered to model those found in the stroke core (Giffard et al.,
1990, 2000; Chesler, 2005). In fact, some studies suggest that
astrocytes may be more vulnerable to ischaemia than neurons
(Garcia et al., 1993; Liu et al., 1999), although this point is
debated (Gurer et al., 2009). Regardless, when astrocyte death
occurs through necrosis, this unstructured loss of intracellular
constituents into the extracellular space would be expected
to enhance stroke damage by increasing inflammation and
oedema.
Given that cell death in the stroke core occurs early and is
overwhelming, research has focused on preventing delayed
neuronal death in the stroke penumbra and reducing the growth
of stroke volume in the hours and days after stroke onset. One
clinical trial manipulated astrocyte function as a means to
diminish the delayed growth of stroke volume. One of the
mechanisms by which astrocytes likely enhance neuronal death
following stroke is through the release of S100b (Matsui et al.,
2002), which is toxic to neurons when present at high levels (Hu
et al., 1997). AA (arundic acid; ONO-2506) was identified through
a chemical screen as a compound that could diminish activation
of astrocytes and S100b expression. In fact, AA reduced delayed
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growth of infarct volume and improved functional outcome
in rodents (Tateishi et al., 2002). The protective effect of AA
was greater if administered 24 h after stroke onset
compared with its administration immediately after stroke
onset, suggesting that its window of efficacy is very much
extended compared with most neuroprotectants. A mul-
tiple-centre trial testing the efficacy of AA to reduce
stroke-related disability was conducted. However, this trial
was terminated early for lack of efficacy. Yet, clinical
studies suggest that growth of stroke volume occurs in a
subset of patients (Sorensen et al., 1996; Beaulieu et al.,
1999; Barrett et al., 2009). As such, this delayed growth of
stroke volume may be a worthy target for future work if this
subset of patients can be reliably identified and targeted.
In the days and weeks after stroke onset, astrocytes release
a number of neuroprotectants including EPO (erythropoie-
tin), VEGF (vascular endothelial growth factor) and glial-
derived neurotrophic factor, all of which may either reduce
ischaemic neuronal damage or improve functional recovery
following stroke (Kitagawa et al., 1999; Zhang et al., 2000;
Hermann et al., 2001; Harvey et al., 2003; Jelkmann and
Wagner, 2004; Chavez et al., 2006). In particular, the
neuroprotective properties of EPO have been studied
(Masuda et al., 1994; Marti et al., 1997; Ruscher et al.,
2002; Prass et al., 2003). For example, EPO reduces neuronal
death with OGD (Ruscher et al., 2002), glutamate toxicity
(Morishita et al., 1997), and nitric oxide induced death
(Sakanaka et al., 1998). Conditioned media taken from
hypoxic astrocyte cultures is protective to neurons exposed
to OGD through the actions of EPO, demonstrating the
importance of astrocytes in mediating neuroprotection under
these circumstances (Chavez et al., 2006). Similar to the in
vitro experiments, protective effects have been described for
EPO in vivo during stroke (Bernaudin et al., 1999; Siren et al.,
2001). Clinical trials were performed to establish the safety
and efficacy of EPO in stroke treatment. An initial Phase II
trial did not identify any safety concerns and suggested
efficacy of EPO protection in acute stroke (Ehrenreich et al.,
2002). A subsequent Phase III double-blinded, placebo-
controlled trial enrolled 522 patients (Ehrenreich et al.,
2009). Patients were treated with EPO within 6 h of the onset
of their symptoms and clinical outcome was evaluated at 30
and 90 days after stroke (Ehrenreich et al., 2009).
Unfortunately, EPO did not improve clinical outcome
compared with the placebo. This negative result reminds us
that all neuroprotective trials are hampered by the problem
of delivery of a compound to a poorly perfused area of brain
within a short time-frame after stroke onset. Yet, EPO could
still be a potential agent to improve functional outcome after
stroke. For example, EPO has multiple restorative functions,
including promoting angiogenesis and neurogenesis (Shingo
et al., 2001; Byts and Siren, 2009; Siren et al., 2009). To
harness the restorative power of EPO in stroke, it is important
to examine the mechanisms by which the temporal
expression of endogenous EPO may be enhanced in
astrocytes following stroke.
The transition from the acute stroke period to the sub-
acute/chronic time frame after stroke can dramatically
change the functional consequences of astrocyte-released
proteins. Both VEGF and MMP-9 (matrix metalloproteinase-9)
have dramatically different effects in the acute versus sub-
acute time frames following onset of ischaemia. VEGF is
expressed in astrocytes, as well as other cell types, during
hypoxia and stroke (Sinor et al., 1998; Lee et al., 1999). While
VEGF is neuroprotective in culture (Jin et al., 2000),
administration of VEGF at the onset of stroke increases
stroke volume (Jelkmann and Wagner, 2004). This patho-
logical effect of VEGF is mediated by the ability of VEGF to
enhance blood–brain barrier permeability, which leads
to brain oedema. In contrast, when administered 2 days
after stroke onset during the sub-acute stroke period, VEGF
enhances angiogenesis and recovery from stroke (Jelkmann
and Wagner, 2004). Thus, the protective or pathological
actions of VEGF are determined by its temporal expression.
Similarly, MMP-9 has pathological or adaptive functions
depending on its temporal expression following stroke (Zhao
et al., 2006). MMPs cleave extracellular matrix proteins,
which are important in modulating cellular interactions
during tissue remodelling in disease and trauma. It is well
described that MMP-9 increases blood–brain barrier per-
meability and increases ischaemia-induced damage during
acute stroke (Cunningham et al., 2005; Jian Liu and
Rosenberg, 2005). In contrast, several days after stroke onset
MMP-9 serves a neuroprotective role by cleaving and
activating VEGF (Zhao et al., 2006). During this delayed
time-frame, MMP is highly expressed on both astrocytes and
neurons. In addition, VEGF localizes primarily to astrocytes,
suggesting that astrocytes significantly contribute to this
protective function of MMP-9. These temporally distinct and
divergent actions of VEGF and MMP-9 demonstrate the
important concept that astrocyte function may change from
a pathological to adaptive depending on the temporal profile
of expression following ischemia. As such, future therapeutics
targeting these functions will need to carefully consider these
critical time windows for intervention.
In the weeks to months following stroke onset, profound
synaptic plasticity occurs in the peri-infarct cortex, which
influences functional recovery (Carmichael, 2003; Nudo,
2007). Astrocytes have prominent roles in modifying synaptic
plasticity and formation of new synapses (see above).
Emerging evidence suggests that astrocytes release extra-
cellular matrix proteins that encourage neurite outgrowth
and plasticity and therefore may be a target for therapeutic
intervention. For example, the TSP1/2 (thrombospondins
1 and 2), which are extracellular glycoproteins, are highly
induced after stroke on astrocytes (Liauw et al., 2008). In
cultures, the application of TSP1/2 enhances synaptogenesis
several fold (Christopherson et al., 2005). Interestingly, in
stroke models, synaptic number and axonal sprouting were
reduced in transgenic knockout mice lacking TSP1/2 function
(Liauw et al., 2008). Recovery of functional tests was also
diminished in these TSP1/2 KO mice. Based on these results,
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designing treatments that increase TSP1/2 function or
astrocyte release of TSP 1/2 may enhance stroke recovery.
Similar to the above discussions, the effect of reactive
astrocytosis is also dependent on its time course after acute
head trauma. The role of reactive astrocytes has traditionally
been viewed as a process leading to glial scar formation,
reducing the ability of the brain to form new synaptic
connections and axon outgrowth. Yet, work over the last
several years has illustrated that reactive astrocytosis
contributes to tissue survival in several conditions, which is
in part dictated by the time course after injury in which it
occurs. One tool for examining reactive astrocytes is by
utilizing transgenic mice with loss of GFAP and vimentin
(Pekny and Nilsson, 2005). These mice have diminished
reactive astrocytosis. Interestingly, the effect of reactive
astrocytosis changes temporally after injury. For example,
after neurotrauma, GFAP2/2:Vimentin2/2 mice have in-
creased loss of synapses during the acute phase of the injury,
but synaptic number is enhanced in the weeks following
acute injury (Wilhelmsson et al., 2004). In stroke, GFAP2/2:
Vimentin2/2 mice have increased stroke volume, suggesting a
protective role under these conditions (Li et al., 2008).
Similarly, ablation of proliferating reactive astrocytes
enhanced spinal cord injury following spinal cord trauma
(Faulkner et al., 2004) and traumatic brain injury (Myer et al.,




Epilepsy or the occurrence of recurrent seizures is a
behavioural syndrome, that is, a component of several
neurological conditions. Several brain foci associated with
seizure generation are populated by increased numbers of
astrocytes. Such foci include hippocampal seizure foci in
temporal lobe epilepsy, several types of mass lesions in the
brain (low-grade astrocytomas, oligodendrogliomas and
arteriovenous malformations) and tuberous sclerosis. Gliotic
scar formation is a prominent feature of human epilepsy
(Foerster and Penfield, 1930; Penfield and Humphreys, 1940).
What is the role of astrocytes in epileptogenesis in these
neurological conditions?
Epileptogenesis literally means the beginning of epilepsy or
spontaneous recurrent seizures. Do astrocytes play a role in
the mechanisms necessary for spontaneous seizures to first
appear or do astrocytes play a role in seizure maintenance in
the chronic stages of epilepsy? There is some evidence to
support a primary role of astrocytes in seizure generation,
particularly in animal models. In the EL (epileptic) mouse the
hippocampus is important for the generation of behavioural
seizures. However, there is no neuronal injury or loss in this
model but an increase in expression of astrocytes around the
age when seizures appear (Drage et al., 2002), and these
astrocytes have reduced glutamate transporters, suggesting a
primary role for astrocytes, perhaps through defective
glutamate clearance at the seizure focus (Ingram et al.,
2001). More direct evidence is found mice in which there is
astrocyte-specific inactivation of the Tsc1 gene (Tsc1 cKO
mice). In these mice, there is an increase in proliferating
GFAP-immunoreactive astrocytes throughout the brain
(Uhlmann et al., 2002), with the most distinctive histological
alterations seen in the hippocampus. What is significant is
that these astrocyte-specific cKO mutant mice did not show
cortical tubers or defects in neocortical lamination. These
mice have electrographically confirmed seizures shortly after
astrocyte proliferation has begun (Uhlmann et al., 2002).
Further, the astrocytes in Tsc1 cKO exhibit decreased
expression of the glutamate transporters GLT-1 and GLAST
and a functional decrease in glutamate transport current in
astrocytes in hippocampal slices and astrocyte cultures (Wong
et al., 2003). Such changes in glutamate transporters may
lead to the extracellular accumulation of glutamate, which
could cause hyperexcitability of neurons and seizures.
Cultured Tsc1-deficient astrocytes and hippocampal slices
from cKO mice also exhibited reduced Kir currents and
decreased expression of specific Kir channel protein subunits
Kir2.1 and Kir6.1. Thus impaired extracellular K+ uptake by
astrocytes may also contribute to neuronal hyperexcitability
and epileptogenesis in this Tsc1 cKO mouse model (Jansen
et al., 2005).
Much of our understanding of the role of glia in human
epilepsy is obtained from the study of seizure foci surgically
removed for the control of medically intractable seizures (de
Lanerolle et al., 2010). The one limitation in studying human
tissue that it is taken from patients is that they have had
seizures for a considerable period (6–20 years) prior to
surgery. Thus it is more difficult to draw conclusions from this
patient group on the role of astrocytes in the early (acute)
stages of epileptogenesis.
The seizure focus that has received the most study is the
hippocampus from patients with medically intractable tem-
poral lobe epilepsy. The examination of such hippocampi
indicates that approximately 40–65% of these hippo-
campi have hippocampal sclerosis. Eighty percent of these
sclerotic patients have an excellent surgical outcome.
The sclerotic hippocampi have a very high density of
astrocytes and these astrocytes have many distinctive
properties compared with astrocytes from non-sclerotic
hippocampi. Differences in these astrocytes are seen in their
cell membrane properties – they show increased expression of
the glutamate receptors mGluR2/3 (metabotropic glutamate
receptor 2/3); mGluR4, mGluR8 and GluR1 receptors that
have an elevated ratio of flip-to-flop mRNA splice variants
(Seifert et al., 2002, 2004). The expression of membrane
transporter molecules is also altered. Prominent among these
are aquaporin 4 molecules, where their polarity of distri-
bution on the astrocytes is altered with reduced expression
on the perivascular end feet and unchanged on the
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membrane facing the neuropil. The GABA (c-aminobutyric
acid) transporter GAT-3 (GABA transporter 3) expression is
increased on protoplasmic astrocytes in regions of relative
neuronal sparing such as dentate gyrus and hilus. There is
some disagreement in the literature as to whether the
glutamate transporters EAAT1 (excitatory amino acid trans-
porter 1) and EAAT2 are also reduced. The membrane Na+
channels and a1C subunit of the calcium ion channels are
also up-regulated, suggesting that astrocytes in sclerotic
hippocampi have a significant change in their membrane
current characteristics. The inwardly rectifying potassium ion
(Kir4.1) channels are also shown to be impaired, significantly
impeding removal of K+ ions from the extracellular space
(Bordey and Sontheimer, 1998; Hinterkeuser et al., 2000;
Schroder et al., 2000). Among the astrocyte specific enzymes,
glutamine synthetase activity is reduced (Eid et al., 2004),
impeding glutamate clearance and thus leading to increases in
extracellular glutamate levels (During and Spencer, 1993). There
is also a reduced capacity for glutamine synthesis and ammonia
detoxification. Levels of other astrocyte specific enzymes such
as GDH (glutamate dehydrogenase), aspartate aminotransferase
and lactate dehydrogenase (Malthankar-Phatak et al., 2006) are
also altered in astrocytes in sclerotic hippocampi.
Gene expression studies in sclerotic hippocampi have also
suggested changes in the expression of several genes
associated with astrocytes. Among those up-regulated are
those involved with immune and inflammatory functions,
including several chemokines and cytokines, class II MHC
antigen genes and interleukins and complement factors
(Aronica et al., 2007; Lee et al., 2007). Several molecules
associated with the astrocyte/microvascular interface are also
altered, in particular increases in EPO-r (EPO receptor), the
MDR1 (multidrug resistance gene-1) encoded P-glycoprotein
(Tishler et al., 1995), CD44 and plectin 1 (Lee et al., 2007),
among others (de Lanerolle et al., 2010).
Associated with the above molecular anatomical changes
in astrocytes in sclerotic hippocampi are also changes in their
function. Some astrocytes in primary cultures derived from
sclerotic hippocampi and in vitro hippocampal slices are
capable of generating action potential-like responses in
response to depolarizing currents (Bordey and Sontheimer,
1998; O’Connor et al., 1998). Astrocytes from sclerotic
hippocampi respond to glutamate with elevated intracellular
Ca2+ release and Ca2+ oscillations and waves (Lee et al., 1995).
Additionally, several lines of evidence suggest that the altered
properties of sclerotic astrocytes, particularly down-regu-
lation of glutamine synthetase, also alter glutamine–glutam-
ate cycling in hippocampal seizure foci resulting in increased
extracellular glutamate levels before and during seizures
(Figure 4).
More recent studies suggest the recognition of two
functional classes of astrocytes. One type, sometimes referred
to as GluR cells, is weakly positive for GFAP, expresses AMPA-
type glutamate receptors and properties akin to NG2 cells.
These cells are excitable (O’Connor et al., 1998). A second type
of cell, the GluT cell, is more strongly GFAP positive, is more
fibrous in appearance and expresses K+ channels, but lack
glutamate receptors (Matthias et al., 2003). Cells similar to
GluR and GluT cells have been recognized in the human
hippocampus, and though both types are found in normal hi-
ppocampi, an almost complete loss GluT cells is reported in
sclerotic hippocampi (Hinterkeuser et al., 2000). It is most
likely that it is these cells that have impaired Kir channels.
Further, the GluR cells in sclerotic hippocampus have
increased levels of the Flip isoform of GluR1 receptor,
suggesting an increased potential for excitability.
Figure 4 Expression of glutamine synthetase immunoreactivity in a non-sclerotic and sclerotic hippocampus
Glutamine synthetase immunoreactivty in the subiculum/CA1 region in a non-sclerotic [non-MTLE (mesial temporal lobe epilepsy)]
(A) and sclerotic (MTLE) (G) hippocampus. Neurologically normal autopsy hippocampus shows a pattern of staining exactly similar to
(A). (B, C) in higher magnification shows GS immunopositive astrocytes in both the subiculum and CA1 area of a normal or non-
sclerotic hippocampus. The sclerotic hippocampus, in which the subiculum does not have neuronal loss shows GS immunoreactive
astrocytes (H), whereas the neuron-depleted astrocyte-rich CA1 area (I) shows depletion of GS in astrocytes. (A and G) Scale
bar50.5 mm. (B, C, H and I) Scale bar5100 mm. Reprinted from The Lancet, 363, Eid T, Thomas MJ, Spencer DD, Runden-Pran E, Lai
JC, Malthankar GV, Kim JH, Danbolt NC, Ottersren OP, de Lanerolle NC, Loss of glutamine synthetase in the human epileptogenic
hippocampus: possible mechanism for raised extracellular glutamate in mesial temporal lobe epilepsy, 28-37, Copyright (2004), with
permission from Elsevier.
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What role do astrocytes play in a mature hippocampal
seizure focus? As the above review suggests, they may play
several roles. (i) Astrocytes may contribute to the high
glutamate levels at seizure foci through defective glutamate
clearance, and additionally active release of glutamate from
GluR (NG2)-like cells due to enhanced intracellular Ca2+
release or by astrocyte swelling due to reduced aquaporin
4 transporters on perivascular end feet (de Lanerolle et al.,
2010). These elevated glutamate levels may activate neurons
in surrounding or adjacent undamaged regions such as the
subiculum to generate seizure activity. (ii) Defective astro-
cytes may contribute increased extracellular potassium in the
seizure focus. Impaired inwardly rectifying K+ channels and
decreased water flux due to reduced AQP transporters in
astrocytic end feet may be contributory factors. (iii) The
presence of excitable GluR or NG2-like cells with more
glutamate-sensitive GluR1 receptors in the sclerotic seizure
focus may directly contribute to an excitable focus. (iv)
Astrocytes may also modulate the microvasculature, leading
to vascular permeability and promoting entry of substances
such as albumin or circulating leucocytes into the brain
parenchyma with consequent seizure promoting effects (de
Lanerolle et al., 2010). (v) The release of inflammatory and
immune factors by astrocytes may also contribute to the
development of the seizure focus in ways that are only just
beginning to be understood.
Another interesting aspect of epilepsy is the destruction
and loss of astrocytic domain organization (Figure 5). Several
groups have shown that in the normal brain cortical and
hippocampal astrocytes are organized in non-overlapping
spatial domains with limited interdigitation of processes of
adjacent cells (Bushong et al., 2002; Ogata and Kosaka, 2002;
Halassa et al., 2007a, 2007b). Through a process termed
‘tiling,’ astrocytic processes grow within exclusive terri-
tories during development when neuronal and vascular
territories are also being established. In the rodent brain,
one astrocytic domain encompasses ,100000 synapses,
whereas this number rises to 2000000 synapses in the brain
of homo sapiens (Bushong et al., 2002; Oberheim et al., 2006).
Each domain represents an area of the neuropil that is under
control of a single astrocyte, being also an entity of synaptic
modulation that is independent of neural networking. All
synapses within one territory will be contacted by processes
from only one single astrocyte. Reactive astrocytes in three
very different murine models of epilepsy (post-traumatic
injury, genetic susceptibility and systemic kainate exposure)
all were associated with a 10-15-fold increase in overlap of
processes of neighbouring astrocytes (Oberheim et al., 2008).
A similar loss of astrocytic domain organization was noted in
tissue surgically resected from patients resilient to medical
treatment. It is important to note that astroglial domain
organization was preserved in APP transgenic mice expressing
a mutant variant of human amyloid precursor protein de-
spite a striking up-regulation in GFAP expression. Thus, while
the functional consequences of loss of astrocytic territories
have not been established, it appears to be specifically linked
to epilepsy. It is tempting to speculate that synapses receiving
input from more than one astrocyte may not function
optimally.
Are these changes in astrocytes in the hippocampal
seizure focus secondary mechanisms in seizure develop-
ment or are they causative? Comparison of these observa-
tions with animal studies discussed above, where
astrocytes appear to have a more primary role in epilepsy,
show that at least some of the astrocytic changes in the
human focus may be causative, in particular impairment of
Kir channels and decreased expression of astrocytic
glutamate transporters.
Figure 5 Organization of reactive astrocytes in a model of post-traumatic epilepsy induced by cortical injection of a ferrous chloride
solution
(A) Site of cortical injury 6 months after injury. The centre of the lesion (yellow asterisk) is surrounded by palisading astrocytes and,
at a greater distance, by hypertrophic astrocytes. The mouse exhibited daily multiple generalized grand mall seizures. (B) Higher
power image of a similar lesion displaying palisading and hyperthrophic astrocytes. White, GFAP; red, Map2; blue, Sytox. (C, D)
Neighbouring astrocytes in control, non-EL brain exhibit little overlap of processes (C), whereas extensive overlap of processes
between two adjacent astrocytes is evident in a mouse with epilepsy (D). Neighbouring astrocytes were duolistically labelled with DiL
(green) or DiD (ref). Scale bar5100 mm (A), 50 mm and 10 mm (B), 10 mm (C, D). See Oberheim et al. (2008) for details.
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Neurocentric views dominate our current understanding of
neurodegeneration, which is generally defined as a process
of neuronal death that underlie specific neurological deficits.
At the same time it becomes clear that idiosyncratic lesions
associated with different forms of neurodegenerative diseases
(such as for example senile plaques or Lewy bodies) appear at
the late stages of neurodegenerative pathologies and massive
neuronal demise signals terminal stages of the disease. Our
knowledge about early stages of neurodegenerative processes
(when arguably the disease can be either halted or slowed
down) is remarkably limited, and yet data accumulate
suggesting that neurodegeneration begins from failures in
brain homoeostasis and alterations in connectivity of neural
networks that signals early cognitive impairments (Terry,
2000; Kano and Hashimoto, 2009; Nedergaard et al., 2010;
Heneka et al., 2010). The many levels of brain homoeostasis
(cellular, micro-architectural, vascular, metabolic, neuro-
transmitter, ion, etc.) are controlled almost solely by
neuroglia; and it is neuroglia that mount brain defence.
With this in mind the progression of majority (if not all) of
CNS disorders are determined by the ability of neuroglia to
keep brain homoeostasis in stressed conditions, and the
failure of glia to maintain homoeostatic balance signals
irreparable damage and ultimate death of the neural tissue
(Giaume et al., 2007). The pathological potential of astroglia
in neurodegeneration is explored only superficially and yet (as
we shall overview below) they seem to be involved in both
early and late stages of many neurodegenerative diseases.
Astroglia in AD (Alzheimer’s disease)
The pathological potential of neuroglia in dementia praecox
was for the first time recognized by Alois Alzheimer, who
found that glia populated senile plaques and closely
contacted damaged neurones (Alzheimer, 1910). Con-
ceptually there are two types of astroglial reactions observed
in AD-affected brain tissues (Figure 6). Astroglial hypertrophy
associated with increased GFAP and S100b levels, all
indicative of generalized astrogliosis, are often observed in
the post-mortem human tissues (Beach and McGeer, 1988;
Griffin et al., 1989; Nagele et al., 2004; Mrak and Griffin,
2005), and similarly astrogliosis is detected in various AD
animal models (Nagele et al., 2003; Rodriguez et al., 2009;
Heneka et al., 2010). There is a degree of correlation between
severity of astrogliosis and cognitive decline, although
reactive astrocytes are not always associated with senile
plaques (Simpson et al., 2010). The levels of GFAP alone
cannot be predictable as little difference in GFAP expression
was found in brains from non-demented and demented
patients (Wharton et al., 2009). The second reaction of
astroglia to AD progression was found recently in an animal
model of familial AD, where reaction is manifest in the
generalized decrease of morphological presence of astrocytes
signalling astroglial atrophy/degeneration. The atrophic
changes in astrocytes were detected in several brain regions,
including hippocampus, pre-frontal and entorhinal cortex
(Olabarria et al., 2010; Kulijewicz-Nawrot et al., 2011;
Olabarria et al., 2011; Yeh et al., 2011). The astroglial atrophy
preceded the appearance of senile plaques and appeared first
(as early as 1-month-old animals) in the entorhinal cortex,
the region earliest affected by the AD pathology. Atrophic
changes in astroglia were also observed in the neocortices
from the post-mortem demented human brains (Senitz et al.,
1995).
Figure 6 Astrocytes in neurodegeneration
(A) Fluorescence micrographs illustrating a normal hippocampal astrocyte
labelled with anti-GFAP antibody with elongated and multiple radial processes
in an old (18 months) control animal. (B) In age-matched 36TG-AD animals,
astrocytes show a morphological atrophy with a significant reduction in cell
soma volume and area as well as a reduction in the number and width of
processes. (C) Confocal image showing hypertrophic astrocytes (green)
concentrated around Ab plaques (red); occasionally some of the astrocytes
show intracellular Ab accumulation (yellow). Scale bar (A and B): 10 mm; (C):
50 mm.
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How do these two concomitant processes may affect
homoeostatic/neuroprotective abilities of astrocytes? The
answer to this question remains virtually unknown; for
example several contradictory reports indicate that astrocytes
in AD brain can participate in both clearance and degradation
of Ab (Guenette, 2003; Nicoll and Weller, 2003) as well as in
the production of the latter (Heneka et al., 2005; Rossner
et al., 2005). Astroglial accumulation and degradation of Ab
was shown in vitro (Wyss-Coray et al., 2003) and was
observed in post-mortem entorhinal preparations (Nagele
et al., 2003). Furthermore, it was found that reactive
astrocytes from AD model mice (Tg2576) express the
amyloid-degrading enzyme neprilysin (Apelt et al., 2003).
Astroglial accumulation of Ab, however, was very rarely
found in 36TG-AD mice (Rodriguez et al., 2009; Olabarria
et al., 2010). At the same time astroglial production of Ab was
also reported: it appeared that, in conditions of chronic stress
or amyloid load, reactive astrocytes begin to express c-
secretase (which normally is expressed only in neurons) and
thus contribute to Ab production (Hartlage-Rubsamen et al.,
2003; Heneka et al., 2005; Rossner et al., 2005). The Ab was
additionally found to remodel astroglial metabolism,
although the data remain similarly controversial: both
increased (Allaman et al., 2010) and decreased (Soucek
et al., 2003; Schubert et al., 2009) glucose utilization by Ab-
treated astrocytes were reported. This polymorphism of
pathological astroglial phenotypes most likely results from
multifaceted glial reaction to AD-like pathology which
includes atrophic and astrogliotic changes.
Astrocytes in ALS
Clinical symptoms of ALS result from rapid progressive
degeneration of motor neurons in the cortex, in the brain
stem and in the spinal cord. Neuroglial reactions are
prominent in ALS and most interestingly the early changes
(observed in the human SOD1G93A transgenic mouse model)
are represented by astroglial degeneration and atrophy which
preceded both neuronal death and clinical manifestation
(Rossi et al., 2008; Rossi and Volterra, 2009). Astrocytes
selectively expressing hSOD1 demonstrated glutamate exci-
totoxicity, and inhibition of SOD1 expression selectively in
astrocytes retarded the ALS progression in transgenic animals
(Yamanaka et al., 2008). At the late disease stages, prominent
astrogliosis is observed, although atrophic astrocytes still can
be visualized (McGeer and McGeer, 2002; Rossi et al., 2008).
Astrocytes in Parkinson’s disease
The pathological role of astrocytes in Parkinson’s disease is
unknown; the late stages of the disease are characterized by
reactive astrogliosis (McGeer and McGeer, 2008; Mena and
Garcia de Yebenes, 2008). The density of astrocytes in the
substantia nigra, which is primarily affected by PD pathology,
is the lowest in the brain (Mena and Garcia de Yebenes,
2008). This may explain specific vulnerability of substantia
nigra neurons to stress factors; in addition, astroglial cells are
known to protect dopaminergic neurones in vitro and
are instrumental for neuronal utilization of L-DOPA (Mena
et al., 1996, 1999; Mena and Garcia de Yebenes, 2008).
Astrocytes in Wernicke encephalopathy
Wernicke encephalopathy, most likely caused by thiamine
deficiency which triggers thalamo-cortical lesions resulting in
ataxia, ophthalmoplegia and mental changes, is an example
of specific astrodegeneration. Indeed the leading mechanism
for the cause of severe excitotoxicity and neuronal death in
Wernicke encephalopathy is the dramatic (up to 70%)
decrease in expression of astroglial glutamate transporters
EAAT1 and EAAT2 that compromises glutamate uptake. The
decrease in EAAT1/EAAT2 was detected in human post-
mortem tissues and in the rat thiamine-deficiency model of
the disease (Hazell, 2009; Hazell et al., 2009). The signs
of astroglial atrophy observed in Wernicke encephalopathy
also include significant decrease in expression of GFAP, of
glutamine synthetase and astroglial GAT-3 (Hazell, 2009;
Hazell et al., 2009).
Astrocytes in non-AD dementia
Astroglial degeneration is also observed in various forms of
non-AD neurodegeneration/dementia. Significant astro-
degeneration and astroglial apoptosis was observed in early
stages of fronto-temporal dementia; the degree of astro-
degeneration was reported to correlate with the severity of
dementia (Broe et al., 2004). In addition to these atrophic
changes, profound astrogliosis was detected in post-mortem
tissues form patients with fronto-temporal dementia
(Kersaitis et al., 2004). In thalamic dementia astrogliosis was
suggested to lead to neuronal death (Potts and Leech, 2005).
HIV-1-associated dementia is also characterized by astro-
gliosis and astrodegeneration; the degree of astroglial loss
was reported to correlate with cognitive deficit (Thompson
et al., 2001; Vanzani et al., 2006).
Astrodegeneration and astrogliosis drive
neurodegeneration?
Analysis of the recent literature indicates the existence of
multifaceted astroglial reactions in the progression of various
neurodegenerative processes. Almost invariably these reac-
tions are represented by astrodegeneration/astroglial atrophy
and reactive astrogliosis. Balance between these two
processes can determine the progression and outcome of
the disease, thus placing astrocytes at the very core
of neurodegenerative pathology (Rodriguez et al., 2009;
Heneka et al., 2010; Verkhratsky et al., 2010; Rodriguez and
Verkhratsky, 2011). Early astrodegeneration, for example, may
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be responsible for initial cognitive impairments that
accompany early stages of neurodegenerative diseases. It is
well demonstrated that the earliest morphological symptoms
of AD are represented by synaptic loss and the extent of this
loss correlates with the degree of dementia (DeKosky and
Scheff, 1990; Terry et al., 1991; Samuel et al., 1994; Coleman
et al., 2004). Astroglial atrophy may indeed be the
mechanism of early synaptic failure in neurodegeneration:
reduced astroglial coverage impacts upon synaptic metabolic
support, synaptic maintenance and neurotransmitter homoeo-
stasis and turnover. Furthermore, astroglial degeneration
affects brain homoeostasis and favours excitotoxicity. At the
more advanced stages of neurodegeneration appearance of
specific lesions triggers reactive astrogliosis and microglial
activation, which acting in concert mount neuroinflammatory
responses that ultimately lead to neuronal death and brain
atrophy. Would this hypothesis survive the scrutiny of
experimental test? Only specifically designed research can
provide an answer.
CONCLUSIONS: POTENTIAL PATHOLOGICAL
CONSEQUENCES OF ASTROCYTE LOSS OR
GAIN OF FUNCTIONS
Based on the many different essential roles played by
astrocytes in the healthy CNS, it appears likely that the loss
of normal functions or gain of abnormal effects by astrocytes
has the potential to lead to neuronal dysfunction or
degeneration. In this regard, the potential for genetic
polymorphisms in different individuals to influence astrocyte
functions and dysfunctions may be of clinical interest. Both
experimental and clinical examples now exist of how loss of
astrocyte functions can precipitate neuronal dysfunction
or degeneration. Transgenic mouse models show that deletion
of genes selectively from astrocytes can lead to non-cell-
autonomous neuronal dysfunction and degeneration. For
example, selective deletion from astrocytes of either the
endoribonuclease, Dicer, or of the Wnt-signalling pathway
gene, APC (adenomatous poliposis coli), in both cases leads to
cell-non-autonomous neuronal degeneration of cerebellar
Purkinje neurons and in the case of Dicer, also of cere-
bellar granule neurons (Tao et al., 2011; Wang et al., 2011a).
Similarly, the loss of function associated with astroglial
atrophy can assume pathological relevance in synaptic
weakening and decreased neuronal support in various forms
of neurodegenerative pathology as discussed above. In
addition, gain-of-function transgenic models indicate that
selective targeting to astrocytes of a mutant form of the SOD
(superoxide dismutase) associated with ALS leads to neuronal
degeneration (Lobsiger and Cleveland, 2007; Nagai et al.,
2007; Yamanaka et al., 2008). As the first recognized clinical
example of an astrocyte genetic disorder, mutations in the
astrocyte protein, GFAP, have been identified as the cause of
neuronal dysfunctions, including seizures, in the human
clinical syndrome known as Alexander disease. The prominent
association of reactive astrocytes with essentially all CNS
insults has the potential for the functions or dysfunctions of
these cells to influence CNS pathologies. Combination of
mouse models of transgenic astrocyte manipulations with
experimental models of CNS injury or disease show that
genetic modulations of reactive astrogliosis and scar
formation can markedly alter tissue repair, disease progres-
sion and functional outcome, such that ablation of astrocytes
and attenuation of certain astrocyte functions exacerbates
disease progression and tissue degeneration and worsens
functional outcome (Bush et al., 1999; Faulkner et al., 2004;
Myer et al., 2006; Drogemuller et al., 2008; Herrmann et al.,
2008, Li et al., 2008; Voskuhl et al., 2009), whereas deletion of
certain astrocyte genes appears to improve outcome in some
situations (Brambilla et al., 2005, 2009; Okada et al., 2006). It
is also important to acknowledge that human astrocytes are
large, complex, and likely terminally differentiated cells.
Astrocytes in rodent brains are several-fold smaller and
maintain the potential for dividing. The much longer lifespan
of humans combined with the more complex population of
astrocytes, suggest that human astrocytes may participate to
an even greater extent to disease progression than observa-
tions in rodent models suggest. Collectively, multiple findings
point towards an enormous, yet incompletely understood,
potential for astrocytes to contribute to, or play primary roles
in, disease processes, tissue repair and functional outcome in
a wide variety of clinical conditions (Sofroniew and Vinters,
2010), including stroke, epilepsy and neurodegenerative
diseases.
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